Accidente cerebrovascular embolico por endocarditis trombotica no bacteriana en pacientes con síndrome antifosfolipido
Palavras-chave:
acv, endocarditis, safResumo
Resumen
El sindrome antifosfolipídico es una trombofilia adquirida, de etiología autoinmune, considerada actualmente una enfermedad sistémica. Exponemos el caso clínico de una paciente joven con diagnóstico de SAF que presentó una endocarditis trombótica no bacteriana como afectación cardiovascular-valvular con complicación embólica y accidente cerebrovascular (ACV) consecuente. Revisamos la literatura destacando los mecanismos fisiopatológcos que permiten comprender la enfermedad y sus complicaciones, los elementos diagnósticos y su valor pronóstico así como las diferentes opciones terapéuticas tanto médicas como quirúrgicas.
Abstract
Stroke and APS.
Embolic stroke by thrombotic non bacterial endocarditis in a Antiphospholipid Syndrome patient.
The antiphospholipid síndrome(APS) is an adquaried trombophilia, considered a systemic autoinmune disorder.We report a patient with APS who presented multiple cerebral infarcts(stroke) as a complication of a thrombotic non bacterial endocarditis.
We review the literature focused on the physiological mechanism that produce this desease and its complications. Clinical features and their pronostic value and the different therapeutic options where also studied.
Downloads
Referências
BIBLIOGRAFÍA
(1)Ruiz Irastorza G, Crowther M, Branch W, Kamashta M A. Antiphospholipid syndrome. Lancet 2010; 376: 1498-509.
(2) Yang P, Kruh J N, Foster C S. Antiphospholipid antibody syndrome. Wolters Kluwer Health/Lippincott Williams&WIlkins 2012; 23: 528-32.
(3)Baviskar R R, Amonkar G P, Chaudhary V A, et al. Evolution of Antiphospholipid Antibody Syndrome. Am Forensic Med Pathol 2012; 33: 303-4.
(4) Lim W, Crowther M A, Eikelboom J W. Management of Antiphospholipid antibody Syndrome. JAMA 2006; 295 N°9: 1050-7.
(5) Gonzalez A, Vergara M, Heredia A, LLanos L, Araos F. Accidente cerebrovascular embólico por endocarditis de Libman-Sacks como manifestación inicial de sindrome antifosfolípido primario en una paciente de 17 años. Rev Md Chile 2013; 141: 1206-10.
(6) Cervera R, Rodríguez-Pintó I, Colafrancesco S, et al. 14th International Congress on Antiphospholipid Antibodies Task Force Report on Catastrophic Antiphospholipid Syndrome. Autoimmun Rev 2014; 13: 699-707.
(7) Lonnebakken M T, Gerdts E. Libman Sacks endocarditis and cerebral embolization in antiphospholipid syndrome. Eur Heart J Cardiovasc Imaging 2008; 9: 192-3.
(8) Correia M, Silva A, Mota-arcia R, Mendes S, Martins L, Santos M. An unusual case of pacemaker endocarditis in patient with antiphospholipid syndrome. Rev Port Cardiol. 2012; 31(4): 309-12.
(9)Casanovas N, Paré C, Azqueta M, Josa M, Fonta J y Sanz G. Trombosis intracardíaca y síndrome antifosfolípido primario. Un caso familiar. Rev Esp Cardiol 2001; 54: 1005-9.
(10) Deo S V, Park J s. Primary Antiphospholipid Antibody Syndrome and Libmann-Sachs Endocarditis. Mayo Clin Proc. 2011; 86(10): 929.
(11) Moustafa S, Patton D J, Balon Y, KiddW T, Alvarez N. Mitral valve surgery for marantic endocarditis and multiple cerebral embolisation. Heart Lung Circ 2013; 22: 545-7.
(12) Amigo M-C What do we know about the cardiac valve lesion in the antiphospholipid syndrome? Lupus 2014; 23: 1259–61.
(13) Suzuki A, Asazuma N, Kikuchi E, et al. Possible primary antiphospholipid syndrome with concurrent diffuse alveolar hemorrhaging and Libman-Sacks endocarditis mimicking catastrophic antiphospholipid syndrome. Intern Med 2012; 51: 813-6.
(14) Hucker W J, Chatzizisis Y S, Steigner M L, Winters G L, Kirshenbaum JM. Myocardial catastrophe. A case of sudden, severe myocardial dysfunction. CIrculation 2014; 130:854-62.
(15) Scoble T, Wijetilleka S, Khamashta M.A. Management of refractory anti-phospholipid syndrome. Autoimmun Rev 2011; 10: 669-73.
(16)Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, et al. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. Lupus 2011;20(2):206-18.
(17) Palomo I, Segovia F, Ortega C, Pierangeli S. Antiphospholipid syndrome: a comprehesive review of a complex and multisystemic disease. Clin Exp Rheumatol 2009;27:668-77.
(18)Bert JS, Abdullah M, Dahle TG, Gertner E. Transcatheter aortic valve replacement for advanced valvular disease in active SLE and APS. Lupus 2013; 22:1046-9.
(19)Danza A, Graña D, Goñi M, Vargas A, Ruiz Irastorza G. Hidroxicloroquina en el tratamiento de las enfermedades autoinmunes. Revista Medica de Chile. De próxima aparición 2016.
Downloads
Publicado
Edição
Seção
Licença
Copyright (c) 2016 Universidad Nacional de Córdoba
Este trabalho está licenciado sob uma licença Creative Commons Attribution-NonCommercial 4.0 International License.
A geração de trabalhos derivados é permitida, desde que não seja feita para fins comerciais. O trabalho original não pode ser usado para fins comerciais.
